Invitrogen Buys Protein Chip Maker Protometrix For Undisclosed Sum
Carlsbad, Calif.-based Invitrogen acquired protein microarray company Protometrix of New Haven, Conn., last week. Financial details of the transaction were not disclosed.
Invitrogen said it hopes the acquisition will add $3-5 million to its revenues this year.
Invitrogen said it will offer Protometrix’s first product, a yeast proteome chip introduced to the market in the fall, this summer. In addition, Invitrogen plans to introduce protein microarrays for analyzing human kinase interactions and activity in the second half of the year.
Protometrix, based in Branford, Conn., was founded in 2001 based on technology developed by Michael Snyder at Yale University.
Lynx’s Revenues Fall, Loss Widens in Q4
Lynx Therapeutics last week reported falling revenues and increased losses for the last quarter of 2003.
Revenues for the quarter fell to $2 million, compared to $4.7 million for the same quarter in 2002. Lynx attributed this decrease primarily to lower fees for its technology and services, and fewer collaborative research projects.
R&D costs decreased to $2.4 million, down from $4.2 million during the year-ago period.
Lynx’s net loss amounted to $3.5 million, or $.65 per share, up from $3 million, or $.69 per share, during the fourth quarter of 2002.
As of Dec. 31, Lynx had cash and cash equivalents of $5.6 million, including $0.7 million in restricted cash.
Genomics Collaborative and Celestar-Lexico Plan Gene Expression Image Database
Genomics Collaborative and Celestar-Lexico Sciences of Japan will collaborate to create a breast cancer gene expression image database, the companies said last week.
In a pilot study, scientists will study the expression of a small number of relevant genes in cancerous and normal tissues, using Celestar’s Large-scale in situ hybridization technology (LiSH) and GCI’s Global Repository of human biological samples. The companies selected the genes using Celestar’s text mining system, MedTAK. Depending on the success of the pilot study, the companies plan to expand the expression database and eventually market it to pharmaceutical companies.
Celestar’s LiSH technology visualizes messenger RNA at the cellular level. GCI’s repository contains 550,000 human tissue, DNA, and serum samples from 120,000 patients worldwide.
Chicago’s Genomics USA Gets Boost From State of Illinois Incubator
The Chicago Illinois Technology Enterprise Center this week announced that Genomics USA was among four companies introduced to its investment portfolio.
Genomics USA is developing DNA and protein microarray technologies for high-throughput microarray products. The company is headquartered at the Chicago Technology Park and has exclusive licenses to technologies covered by patent applications from the Baylor College of Medicine.
Genomics USA plans to use the ITEC investment to obtain preliminary data for SBIR grants and to validate its technologies with selected customers.
Chicago-ITEC provides area companies with business development services and is part of a statewide group of entrepreneurial development centers funded by the Illinois Department of Commerce and Economic Opportunity.
US Genomics, Ionian, Others Receive $48M In Homeland Security Contracts
The US Department of Homeland Security announced last week that it will provide $48 million over 18 months to 14 contractors — among them US Genomics and Ionian Technologies — to create indoor and outdoor pathogen monitoring systems designed to guard against bioterrorist attacks.
The contracts were awarded under the auspices of the Homeland Security Advanced Research Projects Agency. In addition to Woburn, Mass.-based US Genomics and Upland, Calif.-based Ionian, the following companies received contracts: Northrop Grumman Systems, MicroFluidic Systems, Science Applications International, IQuum, Nanolytics, Sarnoff, Brimrose, Johns Hopkins University’s Applied Physics Laboratory, Goodrich, Battelle Memorial Institute, Physical Sciences, and Research Triangle Institute.
Genaissance Completes Acquisition of Lark
Genaissance Pharmaceuticals last week announced stockholder approval and the closing of the acquisition of Houston’s Lark Technologies, in a stock-exchange deal valued at some $19.9 million.